IMVARIA Announces Data Demonstrating Company’s Non-Invasive Digital Biomarker for Predicting Mortality in Interstitial Lung Diseases
BERKELEY, Calif.--(BUSINESS WIRE)-- #digitalbiomarker--IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, today announced data from a study evaluating the company’s lead non-invasive digital biomarker Fibresolve showing the tool’s supplemental ability to predict mortality in patients with interstitial lung disease (ILD). The results will be presented on May...
